Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Meanwhile, Novartis could be looking at another label expansion opportunity with Pluvicto. On Thursday, the company revealed that the phase 3 PSMAddition trial in metastatic hormone-sensitive ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

EAST HANOVER, N.J., March 28, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto ® (lutetium Lu 177 vipivotide tetraxetan) for patients ...